Pluristem Therapeutics, Inc.
MATAM Advanced Technology Park
Building No 20
Haifa,
31905
Israel - Map
Phone: 972 7 4710 7171
Fax: 972 7 4710 7172
Web Site: http://www.pluristem.com
| Pluristem Therapeutics Inc., a development stage bio-therapeutics company, engages in the research, development, and production of placental-derived adherent stromal cells (ASCs). The company also involves in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of various severe degenerative, ischemic, and autoimmune disorders. It develops a pipeline of products that are derived from the human placenta, a non-controversial, non-embryonic, and adult stem cell source. These placental adherent stromal cells (ASCs) are expanded in the companys proprietary PluriX three-dimensional bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. The companys principal product under Phase I clinical trial is PLX-PAD for people suffering from peripheral artery disease. Its pre-clinical products include PLX-IBD for inflammatory bowel diseases; PLX-STROKE for ischemic strokes; PLX-BMT for bone marrow transplantation; and PLX-MS for multiple sclerosis. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Zami Aberman , 55
Exec. Chairman, Chief Exec. Officer and Pres |
$
353.00K | N/A | Mr. Yaky Yanay , 38
Chief Financial Officer, Principal Accounting Officer and Company Sec. |
$
197.00K | N/A | Ms. Daya Lettvin ,
Director of Investor & PR |
N/A
| N/A | Dr. William R. Prather RPh, M. D., 62
Sr. VP of Corp. Devel. |
N/A
| N/A | Prof. Tsvee Lapidot ,
Scientific Advisor of HSC Expansion Technology |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
2.03% Nasdaq 0.00%
Profile
